Unusual Volume: Stocks Trading 50%+ Above Their 30-Day Average Volume

Sep 4: +3.9% to $170.57 on 1.8x average volume, the first gain since fiscal Q1 results reported Sep 1 after the close. Revenue was $479.0 million, up 114.7%, with non-GAAP EPS of $1.20 and a Q2 revenue guide of $525 to $535 million. The stock fell 20.2% on Sep 2 on 29.5 million shares and is still 17.6% below its pre-earnings close of $206.95.

Credo sells the active electrical cables, retimers and optical parts that connect AI accelerators inside data centers, and its results now hinge on a few hyperscaler customers. Non-GAAP gross margin was 68.0% and is guided to 67% to 69%, with GAAP net income of $129.4 million and $764.3 million of cash. The stock is 43.6% below its Jun 22 52-week high of $302.52 and 94.2% above the Mar 30 low of $87.81. A 3.9% bounce on a 3.5% semiconductor-index day is the sector, not a verdict on the quarter; the three-session drawdown is the story the turnover reflects.

Sep 4: -6.4% to $177.05 on 2.8x average volume, after opening 11.2% lower at $167.99. FHFA Director Bill Pulte posted on X Thursday night that Equifax, Experian and TransUnion "have been overcharging Americans for far too long." He added that "this will end soon" and that FHFA is "seriously considering bi-merge, and stronger solutions." On Friday he said FHFA is studying a single credit report. He also instructed Fannie Mae and Freddie Mac to approve all lenders to use VantageScore.

Equifax sells credit reports and workforce data, and mortgage tri-merge reports, one from each bureau per application, are a high-margin recurring line. A move to two reports, or one, removes a third or two thirds of that volume across the industry. TransUnion fell 5.9% and Fair Isaac 16.7% on the same posts. The Mortgage Bankers Association said lenders reported 40% to 50% average increases in credit-reporting costs for 2026. The stock is 32.5% below its Sep 17, 2025 52-week high of $262.33 and 16.5% above the Jun 25 low of $151.93. Nothing has been ordered on bi-merge yet; watch for a formal FHFA directive to the enterprises, which is what would change revenue.

Sep 4: +5.1% to $252.20 on 1.6x average volume, recovering the Sep 3 reversal that followed Q2 results reported Sep 2 after the close. Net sales rose 22.9% to $1.26 billion on a 14.1% comparable-sales gain, and adjusted EPS was $1.68. Full-year guidance rose to $5.63 to $5.71 billion of sales and $9.83 to $10.31 of adjusted EPS, from $8.65 to $9.05. On Sep 3 the stock opened 5.7% higher at $257.00 and closed down 1.3%.

Five Below is a value retailer for kids and teens with 2,022 stores in 46 states after 52 net openings in the quarter. GAAP EPS of $3.99 included $163.6 million of pre-tax tariff refunds under IEEPA, which is why the adjusted figure is the one to use. Q3 is guided to $1.21 to $1.23 billion of sales and comps of 8% to 10%, a deceleration from 14.1%; full-year comps are guided to 10% to 12%. The stock is 4.0% below its Aug 24 52-week high of $262.72 and 82.1% above the Oct 10, 2025 low of $138.49. Two sessions of two-way trade on a beat-and-raise say the debate is the comp deceleration, not the quarter.

Sep 4: +15.2% to $28.65 on 4.2x average volume after Tyra set a date for its SURF302 readout. An 8:00 am ET release said the company will host a call on Wednesday, Sep 9 at 8:00 am ET to present initial results. SURF302 is the Phase 2 study of oral dabogratinib in intermediate-risk non-muscle invasive bladder cancer. The date is the news; no data was released.

Tyra is a clinical-stage biotech built around FGFR3-selective inhibitors, and dabogratinib is its lead program. The Aug 4 quarterly report guided the readout to safety data on more than 40 patients and efficacy on more than 20, across the 50 mg and 60 mg daily doses. Cash was $353.9 million at Jun 30, with runway into the second half of 2028. The stock is 27.7% below its Apr 2 52-week high of $39.61 and 142% above the Sep 9, 2025 low of $11.82. The put-side signature two sessions before a binary readout reads as protection on a stock that just rallied into it, not a call on the data.

Sep 2: +13.9% on roughly 3.5x normal volume to $23.39, with no company release dated to the session. The only dated driver is Baird's Aug 31 upgrade to Outperform from Neutral (target $29 from $20), citing equipment inventory down nearly $600 million from its fiscal 2025 second-quarter peak; the whole ag-equipment complex extended its run on Sep 2 (CNH +9.2%, Deere +3.3%, AGCO +3.6%).

Titan Machinery is a CNH-brand farm and construction equipment dealer, so it trades as a leveraged version of the manufacturers' cycle. Baird's case is that destocking is done, the stock trades under 1.0x tangible book, and normalized earnings power exceeds $3 a share. Note the timing gap: the note came Monday and the stock did nothing Tuesday, so Sep 2 reads as sector momentum catching a small-cap late. The stock is 3.1% below its 52-week high of $24.13.